Generation of a high-capacity hybrid vector: packaging of recombinant adenoassociated virus replicative intermediates in adenovirus capsids overcomes the limited cloning capacity of adenoassociated virus vectors.
Gene therapy aims to complement or, ideally, correct defective genes. The broad clinical application of this emerging technology requires the development of safe high-capacity gene delivery vehicles that combine efficient transduction of dividing as well as quiescent cells with sustained transgene expression. Here we present a new hybrid vector system that unites favorable attributes of adenoassociated virus (AAV) and adenovirus (Ad) vectors in a single particle. This was achieved by inclusion of Ad packaging elements in different sized recombinant AAV genomes. In the presence of AAV replicative functions and a recombinant helper Ad, AAV/Ad hybrid particles were generated via encapsidation of AAV-dependent replicative intermediates into Ad capsids. In stringent in vitro models based on transduction of proliferating cells we show that AAV/Ad hybrid vectors are superior to Ad vectors in establishing prolonged transgene expression and can be used to deliver DNA fragments of at least 27 kb.
Gonçalves
M A
MA
Gene Therapy Section, Department of Molecular Cell Biology, Leiden University Medical Center, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands. M.Goncalves@lumc.nl
Pau
M G
MG
de Vries
A A
AA
Valerio
D
D
D000260:Adenoviruses, Human / Q000235:genetics* / Q000502:physiology; D002213:Capsid / Q000235:genetics*; D002461:Cell Line, Transformed; D000229:Dependovirus / Q000235:genetics* / Q000502:physiology; D015870:Gene Expression; D005822:Genetic Vectors / Q000235:genetics* / Q000502:physiology; D016679:Genome, Viral; D006801:Humans; D011995:Recombination, Genetic; D019076:Transgenes; D014771:Virion; D019065:Virus Assembly / Q000235:genetics / Q000502:physiology*; D014779:Virus Replication / Q000235:genetics / Q000502:physiology*